The hypoactive sexual desire disorder treatment market is set to expand at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Hypoactive sexual desire disorder (HSDD) can be primary, secondary, lifelong or situational; currently physicians worldwide are employing either psychotherapy or pharmacotherapy for its treatment. Recent approval of Bremelanotide (Vyleesi) will propel the HSDD market growth in the near future. Currently 2 drugs such as Prasterone 6.5 mg vaginal insert and BP101 are under phase 3 clinical trial being investigated for its safety and efficacy for treating HSDD.
Market Synopsis
Get a sample copy for more information
"Multifunctional serotonin agonist and antagonist pharmacodynamic profile increases the popularity of flibanserin for treating HSDD"
Hypoactive sexual desire disorder (HSDD) is the absence of sexual thoughts and fantasies causing low libido and sex drive in women population worldwide. The neurochemical basis associated with HSDD in not fully understood but low sex desire has been associated with hyperfunctional inhibition and hypofunctional excitation or a combination of both regulated by neuromodulators. Fluctuating sex hormones during menstrual cycle is also a chief contributing factor for the occurrence of HSDD in women population worldwide. The diagnosis of HSDD is challenging and physicians rely on pharmacotherapy and psychotherapy for its treatment. The PLISSIT model (Permission, Limited Information, Specific Suggestions and Intensive Therapy) aids in initial screening of HSDD. Cognitive behavior therapy is opted in patients responding to counseling sessions with sex therapist. In pharmacotherapy antidepressants such as bupropion and buspirone have been used as off label treatment for HSDD in women showing low sex drive associated with anxiety and depression. Testosterone transdermal patches are used as an off label treatment in premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by USFDA for treating HSDD in premenopausal women by decreasing serotonin activity and increasing norepinephrine and dopamine activity simultaneously.
Get a sample copy for more information
"Increasing stress and fluctuating hormones are responsible for low sex drive in women population in North America region"
North America holding a share of 38.5% is currently the clear leader in the regional segment for hypoactive sexual desire disorder (HSDD) treatment market. The chief contributing factors for the growing incidence of low sex drive in the women population in the North America region are increasing stress in daily life and fluctuating hormones associated with menstrual cycle. Presence of pharmaceutical companies engaged in the drug development for treating HSDD such as Allergan, Plc., AMAG Pharmaceuticals, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc etc. further bolster the market growth in the region. Europe accounts for 32.4% market share owing to favorable reimbursement scenario for drugs prescribed for the treatment of HSDD. Asia Pacific represents 15.2% market share and is ready to register faster growth during the forecast period primarily due to rising incidence of stress in working women population and developing healthcare infrastructure.
Get a sample copy for more information
Historical & Forecast Period
This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by therapy and by geography.
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Therapy (2017–2027; US$ Mn)
• Buspirone
• Bupropion
• Testosterone
• Flibanserin
• Bremelanotide
• Cognitive Behavior Therapy
|
|
Geography Segment (2017–2027; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of APAC)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of Middle East and Africa)
|
Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceutcials, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc. and Sprout Pharmaceutcials, Inc.
Key questions answered in this report
- What are the strategic collaboration, merger and acquisition taking place in the HSDD treatment market?
- Which pharmaceutical companies are providing pharmacotherapy drugs for treating HSDD?
- What is the pathophysiology associated with HSDD and the treatment regimen adopted by physicians worldwide?
- What is the market size and CAGR of developed regional segments such as North America and Europe in the HSDD treatment market?
